9780898387124 - screening for biological response modifiers: methods and rationale: 29 (developments in oncology, 29) de fidler, isaiah j.; talmadge, james e.; oldham, r.k. (12 resultados)
Idioma: Inglés
Editorial: Springer 1985
Serie: Developments in Oncology, Libro 21 de 78. Libro 21 de 78 - Developments in Oncology
- Tapa dura
Librería: Ria Christie Collections, Uxbridge, Reino UnidoRia Christie Collections
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 114,66
Envío por EUR 13,87Se envía de Reino Unido a Estados Unidos de AmericaCantidad disponible: Más de 20 disponibles
Condición: New. In.
Idioma: Inglés
Editorial: Kluwer Academic Publishers 1985
Serie: Developments in Oncology, Libro 21 de 78. Libro 21 de 78 - Developments in Oncology
- Tapa dura
Librería: Kennys Bookshop and Art Galleries Ltd., Galway, IrlandaKennys Bookshop and Art Galleries Ltd.
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 133,31
Envío por EUR 10,50Se envía de Irlanda a Estados Unidos de AmericaCantidad disponible: 15 disponibles
Condición: New. Series: Developments in Oncology. Num Pages: 194 pages, black & white illustrations. BIC Classification: MJCL. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly. Dimension: 234 x 156 x 12. Weight in Grams: 476. . 1985. Hardback. . . . .
Idioma: Inglés
Editorial: Springer 1985
Serie: Developments in Oncology, Libro 21 de 78. Libro 21 de 78 - Developments in Oncology
- Tapa dura
Librería: Books Puddle, New York, Estados Unidos de AmericaBooks Puddle
Contactar con el vendedorVendedor de 4 estrellasCondición: Nuevo
EUR 159,79
Envío por EUR 3,44Se envía dentro de Estados Unidos de AmericaCantidad disponible: 4 disponibles
Condición: New. pp. 212.
Idioma: Inglés
Editorial: Kluwer Academic Publishers 1985
Serie: Developments in Oncology, Libro 21 de 78. Libro 21 de 78 - Developments in Oncology
- Tapa dura
Librería: Kennys Bookstore, Olney, Estados Unidos de AmericaKennys Bookstore
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 165,86
Envío por EUR 9,05Se envía dentro de Estados Unidos de AmericaCantidad disponible: 15 disponibles
Condición: New. Series: Developments in Oncology. Num Pages: 194 pages, black & white illustrations. BIC Classification: MJCL. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly. Dimension: 234 x 156 x 12. Weight in Grams: 476. . 1985. Hardback. . . . . Books ship from the US and Ireland.
Idioma: Inglés
Editorial: Springer US, Springer US 1985
Serie: Developments in Oncology, Libro 21 de 78. Libro 21 de 78 - Developments in Oncology
- Tapa dura
Librería: AHA-BUCH GmbH, Einbeck, AlemaniaAHA-BUCH GmbH
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 114,36
Envío por EUR 62,45Se envía de Alemania a Estados Unidos de AmericaCantidad disponible: 1 disponibles
Buch. Condición: Neu. Druck auf Anfrage Neuware - Printed after ordering - The observation in the 1950s that nitrogen mustard and other toxic chemicals could induce antitumor responses in patients with refractory lymphoma initiated a massive search for active chemotherapeutic agents. The initial observations stimulated a search…for new chemotherapeutic agents which might have increased antitumor activity with less toxicity for normal tissues. To aid in the search for these new chemicals and to attempt to distinguish among the many toxic chemicals which might be candidates for clinical studies, the National Cancer Institute, the pharmaceutical industry, and the cancer research laboratories of most Western nations developed systems for 'screening' drugs for antitumor activity. Perhaps the most extensive screening program was established by the National Cancer Institute (1). This screening program has evolved over the last two decades, an evolution which has been repeatedly reviewed (2-5). Various screening programs in use have examined over 500,000 compounds as potential anticancer agents. From these, there are now approximately forty anticancer drugs in clinical use. The utiliy of these compounds and their toxicities have been reviewed on many occasions. It is now apparent that more active and less toxic anticancer drugs are needed. It is also clear that the current screening programs are identifying compounds with similar levels of activity and with continuing moderate to severe toxicity (6).
Idioma: Inglés
Editorial: Springer 1985
Serie: Developments in Oncology, Libro 21 de 78. Libro 21 de 78 - Developments in Oncology
- Tapa dura
Librería: Mispah books, Redhill, Reino UnidoMispah books
Contactar con el vendedorVendedor de 4 estrellasCondición: Usado - Bueno
EUR 184,85
Envío por EUR 28,95Se envía de Reino Unido a Estados Unidos de AmericaCantidad disponible: 1 disponibles
Hardcover. Condición: Very Good. Very Good. book.
Idioma: Inglés
Editorial: Springer US Apr 1985 1985
Serie: Developments in Oncology, Libro 21 de 78. Libro 21 de 78 - Developments in Oncology
- Tapa dura
- Impresión bajo demanda
Librería: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, AlemaniaBuchWeltWeit Ludwig Meier e.K.
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 106,99
Envío por EUR 23,00Se envía de Alemania a Estados Unidos de AmericaCantidad disponible: 2 disponibles
Buch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -The observation in the 1950s that nitrogen mustard and other toxic chemicals could induce antitumor responses in patients with refractory lymphoma initiated a massive search for active chemotherapeutic agents. The initial observations stim…ulated a search for new chemotherapeutic agents which might have increased antitumor activity with less toxicity for normal tissues. To aid in the search for these new chemicals and to attempt to distinguish among the many toxic chemicals which might be candidates for clinical studies, the National Cancer Institute, the pharmaceutical industry, and the cancer research laboratories of most Western nations developed systems for 'screening' drugs for antitumor activity. Perhaps the most extensive screening program was established by the National Cancer Institute (1). This screening program has evolved over the last two decades, an evolution which has been repeatedly reviewed (2-5). Various screening programs in use have examined over 500,000 compounds as potential anticancer agents. From these, there are now approximately forty anticancer drugs in clinical use. The utiliy of these compounds and their toxicities have been reviewed on many occasions. It is now apparent that more active and less toxic anticancer drugs are needed. It is also clear that the current screening programs are identifying compounds with similar levels of activity and with continuing moderate to severe toxicity (6). 212 pp. Englisch.
Idioma: Inglés
Editorial: Springer US 1985
Serie: Developments in Oncology, Libro 21 de 78. Libro 21 de 78 - Developments in Oncology
- Tapa dura
- Impresión bajo demanda
Librería: moluna, Greven, Alemaniamoluna
Contactar con el vendedorVendedor de 4 estrellasCondición: Nuevo
EUR 92,27
Envío por EUR 48,99Se envía de Alemania a Estados Unidos de AmericaCantidad disponible: Más de 20 disponibles
Gebunden. Condición: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. The observation in the 1950s that nitrogen mustard and other toxic chemicals could induce antitumor responses in patients with refractory lymphoma initiated a massive search for active chemotherapeutic agent…s. The initial observations stimulated a search fo.
Idioma: Inglés
Editorial: Springer 1985
Serie: Developments in Oncology, Libro 21 de 78. Libro 21 de 78 - Developments in Oncology
- Tapa dura
- Impresión bajo demanda
Librería: Majestic Books, Hounslow, Reino UnidoMajestic Books
Contactar con el vendedorVendedor de 4 estrellasCondición: Nuevo
EUR 163,03
Envío por EUR 7,53Se envía de Reino Unido a Estados Unidos de AmericaCantidad disponible: 4 disponibles
Condición: New. Print on Demand pp. 212 52:B&W 6.14 x 9.21in or 234 x 156mm (Royal 8vo) Case Laminate on White w/Gloss Lam.
Más imágenesIdioma: Inglés
Editorial: Springer US 1985
Serie: Developments in Oncology, Libro 21 de 78. Libro 21 de 78 - Developments in Oncology
- Tapa dura
- Impresión bajo demanda
Librería: preigu, Osnabrück, Alemaniapreigu
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 95,70
Envío por EUR 70,00Se envía de Alemania a Estados Unidos de AmericaCantidad disponible: 5 disponibles
Buch. Condición: Neu. Screening for Biological Response Modifiers: Methods and Rationale | James E. Talmadge (u. a.) | Buch | xiv | Englisch | 1985 | Springer US | EAN 9780898387124 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter:… preigu Print on Demand.
Idioma: Inglés
Editorial: Springer US, Springer US Apr 1985 1985
Serie: Developments in Oncology, Libro 21 de 78. Libro 21 de 78 - Developments in Oncology
- Tapa dura
- Impresión bajo demanda
Librería: buchversandmimpf2000, Emtmannsberg, Alemaniabuchversandmimpf2000
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 106,99
Envío por EUR 60,00Se envía de Alemania a Estados Unidos de AmericaCantidad disponible: 1 disponibles
Buch. Condición: Neu. This item is printed on demand - Print on Demand Titel. Neuware -The observation in the 1950s that nitrogen mustard and other toxic chemicals could induce antitumor responses in patients with refractory lymphoma initiated a massive search for active chemotherapeutic agents. The initial observations stimulat…ed a search for new chemotherapeutic agents which might have increased antitumor activity with less toxicity for normal tissues. To aid in the search for these new chemicals and to attempt to distinguish among the many toxic chemicals which might be candidates for clinical studies, the National Cancer Institute, the pharmaceutical industry, and the cancer research laboratories of most Western nations developed systems for 'screening' drugs for antitumor activity. Perhaps the most extensive screening program was established by the National Cancer Institute (1). This screening program has evolved over the last two decades, an evolution which has been repeatedly reviewed (2-5). Various screening programs in use have examined over 500,000 compounds as potential anticancer agents. From these, there are now approximately forty anticancer drugs in clinical use. The utiliy of these compounds and their toxicities have been reviewed on many occasions. It is now apparent that more active and less toxic anticancer drugs are needed. It is also clear that the current screening programs are identifying compounds with similar levels of activity and with continuing moderate to severe toxicity (6).Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 212 pp. Englisch.
Idioma: Inglés
Editorial: Springer 1985
Serie: Developments in Oncology, Libro 21 de 78. Libro 21 de 78 - Developments in Oncology
- Tapa dura
- Impresión bajo demanda
Librería: Biblios, frankfurt am main, AlemaniaBiblios
Contactar con el vendedorVendedor de 4 estrellasCondición: Nuevo
EUR 165,28
Envío por EUR 9,95Se envía de Alemania a Estados Unidos de AmericaCantidad disponible: 4 disponibles
Condición: New. PRINT ON DEMAND pp. 212.
